SynthesisFrontiers in immunology2026
Sex and risk of hyperprogressive disease in cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hyperprogressive disease (HPD) refers to a phenomenon characterized by a significant acceleration in tumor growth during treatment with immune-checkpoint inhibitors (ICIs), far exceeding the pre-treatment growth rate, leading to rapid deterioration in the patient's condition. HPD typically occurs within the first two months of treatment and often results in early mortality. While sex differences in immune responses have been extensively studied, the relationship between sex and HPD risk remains unclear. Methods: We systematically searched MEDLINE (PubMed), Embase, and Scopus databases to identify studies reporting HPD in patients treated with ICIs, with available gender-stratified data. The search encompassed all records from database inception until 30 June 2025. Meta-analyses were performed using RevMan 5.4.1 software, with pooled odds ratios and 95% confidence intervals calculated under either fixed-effects or random-effects model, depending on heterogeneity. The primary objective was to evaluate the association between biological sex and the risk of HPD. The research protocol has been registered on the PROSPERO platform (CRD420261324007). Results: This meta-analysis included 20 studies involving 2,291 patients (1,612 male patients and 679 female patients), all of which were retrospective. The overall incidence of HPD was 18.67% in male patients and 18.26% in female patients. Pooled analysis revealed no statistically significant association between biological sex and the risk of HPD development ( Conclusion: Our findings demonstrate that sex should not be considered a determinative factor for HPD risk in patients receiving ICIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.